Ansa Biotechnologies, Inc. today announced its speaker lineup for presentations at the upcoming Global Synthetic Biology (SynBioBeta) Conference in San Jose, Calif., from May 6-9, 2024.
Several prominent scientists will share insights gained from ability to synthesize complex DNA sequences that were previously impossible with legacy technologies
EMERYVILLE, Calif.--(BUSINESS WIRE)-- Ansa Biotechnologies, Inc., the trusted partner for complex DNA synthesis, today announced its speaker lineup for presentations at the upcoming Global Synthetic Biology (SynBioBeta) Conference in San Jose, Calif., from May 6-9, 2024. The company is also expanding its early access program for complex DNA synthesis. Meeting attendees will be able to learn how to participate in the program throughout the conference in booth #312.
Featured Presentations
From Complexity to Commercialization: The DNA Synthesis Saga Continues
Main Stage on Tuesday, May 7, 9:10 am PDT
Featured panel participant: Jason T. Gammack, CEO of Ansa Biotechnologies
Expand Your Design Space: Ask Bigger Questions with Complex DNA Synthesis
Main Stage on Tuesday, May 7, 12:05 pm PDT
Jason T. Gammack
Embrace Complexity: Insights from the Cutting Edge of Enzymatic DNA Synthesis
Breakout session on Tuesday, May 7, 2:45 pm PDT
- Olga Bielska, PhD, Buck Institute for Research on Aging
- Greg Lohman, PhD, New England Biolabs
- Tae Seok Moon, PhD, Engineering Biology Research Consortium
- Jaymin Patel, PhD, University of California, Berkeley
Ansa’s synthesis services are based on its proprietary technology, which enables ultra-rapid production of complex DNA sequences that can be difficult or even impossible to produce with legacy synthesis techniques. The enzymatic approach eliminates the need for harsh chemicals and does not damage the growing DNA molecule as it is made, which allows for the direct and accurate synthesis of sequences that can be hundreds, and potentially thousands, of bases long. Customers around the world are now taking advantage of these services to develop critical advancements in therapeutics, vaccines, biomanufacturing, agriculture, and more.
“Ansa is enabling a new wave of innovation in healthcare and life science research,” said Mr. Gammack. “We are looking forward to meeting with the SynBioBeta attendees, sharing some of our early access success stories, and learning more about how we can help members of this community push the limits of their research by delivering complex DNA sequences for their most ambitious projects.”
Ansa is now building on the success of its limited early access program and increasing availability to its complex DNA synthesis services. The program offers DNA sequences in both sequence-perfect clonal DNA or faster sequence-verified linear dsDNA fragment formats. To learn more about how to participate in the expanded early access program, visit ansabio.com/early-access.
About Ansa Biotechnologies
Ansa Biotechnologies is enabling customers to push the limits of their scientific projects by delivering DNA sequences that can be difficult or even impossible to produce with legacy synthesis techniques. Ansa’s unique services feature the company’s proprietary synthesis technology, which enables ultra-rapid enzymatic production of complex DNA sequences. This novel approach is poised to accelerate innovation across healthcare, life science research, and other industries powered by synthetic DNA. Ansa is headquartered in Emeryville, CA. For more information, visit ansabio.com or follow on X and LinkedIn.
Ansa Biotechnologies and the Ansa Biotechnologies logo are trademarks of Ansa Biotechnologies, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240430607044/en/
Source: Ansa Biotechnologies, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20240430607044/en
